文献速递甲状腺疾病

TERT mRNA表达作为甲状腺乳头状癌新型预后标志物

TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas.
PubMed 文献 · Thyroid · 2019-08-05

该研究分析159例甲状腺乳头状癌(PTC)样本,用直接测序检测TERT启动子突变,用qRT-PCR测TERT mRNA表达,并用ddPCR复查低等位基因频率突变。结果显示12.6%存在TERT启动子突变,但40.3%突变阴性肿瘤也表达TERT,且突变阴性/表达阳性者复发风险显著更高,提示TERT mRNA表达可作为预后标志物。

要点

  • TERT启动子突变见于12.6%的PTC,与侵袭性临床病理特征相关
  • 40.3%突变阴性PTC仍表达TERT mRNA,且复发风险显著升高
  • TERT mRNA表达可能对年轻PTC患者尤其有预后价值

核心结论

  • TERT启动子突变与PTC侵袭性临床病理特征强相关
  • 无TERT启动子突变的PTC也可高表达TERT mRNA且复发率显著更高
  • TERT mRNA表达可作为PTC预后标志物,尤其适用于年轻患者

研究设计与样本

  • 回顾性分析159例PTC样本
  • 直接DNA测序检测TERT启动子突变
  • qRT-PCR检测TERT mRNA表达
  • ddPCR高灵敏度检测低等位基因频率TERT启动子突变

主要发现

  • 20例(12.6%)检出TERT启动子突变
  • 139例突变阴性肿瘤中56例(40.3%)表达TERT
  • ddPCR在3例(5.4%)突变阴性样本中检出低等位基因频率TERT启动子突变
  • 突变阴性/表达阳性肿瘤复发风险显著高于突变阴性/表达阴性肿瘤
  • 突变阴性PTC中TERT表达水平与患者年龄及BRAF突变呈负相关

关键数值与推荐

  • TERT启动子突变阳性率12.6%(20/159)
  • 突变阴性肿瘤TERT表达阳性率40.3%(56/139)
  • ddPCR检出低等位基因频率突变比例5.4%(3/56)
  • 按TERT表达水平第80百分位分组后,高表达组复发风险比更高

临床怎么用

  • 对PTC患者可考虑检测TERT mRNA表达以辅助预后评估
  • TERT启动子突变阴性但mRNA高表达者仍需警惕复发风险
  • 年轻PTC患者中TERT mRNA表达可能弥补启动子突变检测的不足

局限性

  • 样本量有限(159例)
  • 回顾性设计
  • ddPCR仅复查部分突变阴性样本
  • TERT表达阈值(第80百分位)需外部验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Telomerase reverse transcriptase (TERT) promoter mutations have been found in a subset of papillary thyroid carcinomas (PTCs) and are associated with tumor aggressiveness and worse prognosis. However, little is known about the status of TERT mRNA expression and its relationship between TERT promoter mutations and clinicopathological features. Methods: We analyzed 159 PTC samples for TERT promoter mutations using direct DNA sequencing. TERT expression was measured using quantitative reverse transcription polymerase chain reaction. To examine low allelic frequency of TERT promoter mutations with high sensitivity, we used droplet digital polymerase chain reaction (ddPCR). The relationship between the status of the TERT promoter mutation/expression and clinicopathological features including recurrence risk was statistically analyzed. Results:TERT promoter mutations were found in 20 cases (12.6%). However, TERT expression was observed not only in the mutation-positive tumors but also in 56 of 139 (40.3%) mutation-negative tumors. Among them, we detected low allelic frequency of TERT promoter mutations in three samples (5.4%) using ddPCR. We confirmed a significant association between TERT promoter mutations and aggressive clinicopathological features in this series. The risk of recurrence of TERT mutation-negative/expression-positive tumors was significantly higher than that of the mutation-negative/expression-negative tumors, suggesting that TERT expression even in absence of a mutation confers a negative influence on PTCs. Moreover, when we reclassified the mutation-negative cases into two groups based on the TERT expression levels: expression-negative/expression levels <80th percentile and expression levels >80th percentile because minimal expression may have a negligible clinical impact, a higher hazard ratio for recurrence was observed. Interestingly, TERT expression levels in the mutation-negative PTCs were inversely correlated with patient age and the presence of BRAF mutations. Conclusions: We confirm a strong correlation between the presence of TERT promoter mutations and aggressive clinicopathological features in this PTC series. In addition, there were PTCs showing high TERT mRNA expression even in the absence of TERT promoter mutations. These cases also showed a significantly higher recurrence rate. Since the TERT promoter mutations are observed only in elderly patients, TERT mRNA expression can be a useful prognostic marker especially in younger PTC patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tanaka A, Matsuse M, Saenko V, et al. TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas. Thyroid. 2019. PMID: 31286848. doi:10.1089/thy.2018.0695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。